Flurandrenolide (Flurandrenolide) Patent Expiration, LOE Window & CMS Spending

Flurandrenolide (Flurandrenolide) by Padagis: Multi-Source Generic Molecule, 0 AB generics, $223K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPadagis
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$223K
2024 Medicare Part D Spend$72K
2024 Medicaid Spend$151K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel